Hims & Hers Health, Inc. Stock: CFO Sold $229K Before Key FDA Vote

Hims & Hers Health, Inc. stock sits in tense equilibrium after a sharp intraday reversal on July 23. Closing at $33.36 — right at its pivot of $33.34 — HIMS faces a neutral technical regime. An FDA advisory committee meeting, insider share sales, and elevated volatility place the stock at a genuine crossroads.

Key takeaways

• HIMS closed at $33.36 on July 23, essentially flat against its pivot point of $33.34.
• The daily RSI at 50.95 signals perfect indecision, while the MACD histogram at -0.65 shows fading momentum.
• The FDA advisory committee meeting (July 23–24) on peptide compounding rules is the dominant near-term catalyst.
• A daily close above $34.66 (Bollinger midline) would signal a bullish reversal; a break below $30.85 would confirm bearish control.
• CFO share sale of approximately $229,000 and the chief accounting officer’s departure add governance-related uncertainty.

Daily Timeframe: Neutral Regime, But Structure Is Shifting

The daily chart shows HIMS in a neutral regime. Price is sandwiched between the EMA20 at $33.55 and EMA200 at $33.05. That compression rarely persists for long. The stock closed at $33.36 on July 23, essentially flat against its pivot point of $33.34. Meanwhile, the EMA50 sits further below at $31.31.

… Continue reading the full article at the original source below.